Compare Boston Beer Company Inc (SAM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs GeneDx Holdings Corp — how do they compare? Boston Beer Company Inc trades at $170.51 (market cap $1.76B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Boston Beer Company Inc and GeneDx Holdings Corp are close in size by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 59 Days and GeneDx Holdings Corp for 19 Days on average.
| SAM | WGS | |
|---|---|---|
Market Cap | $1.76B | $2.02B |
Volume | 264,496 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $167.51 |
52-Week Low | $161.08 | $34.51 |
Typical Hold Time | 59 Days | 19 Days |
Enterprise Value | $1.53B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $171.17, up 1.79% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with a P/E of 22.66 and negative net margin of -3.64%, though operating cash flow remains strong at $270M. Recent news highlights brand innovation including new cocktail products and marketing partnerships, while analyst consensus leans heavily toward Hold with a $204.44 price target.
SAM faces headwinds from declining volumes and cost pressures, but brand investments and new product launches offer growth potential. The stock trades near analyst low targets with institutional interest growing, though profitability concerns and competitive pressures present significant risks for investors seeking turnaround opportunities in the challenging beverage sector.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
